Literature DB >> 10595583

SHP1 protein tyrosine phosphatase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells.

T Bittorf1, J Seiler, Z Zhang, R Jaster, J Brock.   

Abstract

The SH2 domain-containing tyrosine phosphatase SHP1 is known to play a crucial role in the regulation of hematopoiesis. It has been shown previously that SHP1 associates with the activated erythropoietin receptor (EPOR) and negatively regulates mitogenic signaling. To further elucidate the role of SHP1 in erythropoietin (EPO)-induced cellular responses we employed J2E erythroleukemic cells as a model for erythroid maturation and cytokine-triggered suppression of apoptosis. Our data indicate that overexpressed SHP1 inhibits both EPO-induced differentiation as well as prevention of apoptosis. The specific signaling pathways responsible are not unraveled so far. Therefore, we analyzed the involvement of SHP1 in two established EPO-stimulated pathways, the JAK/STAT and the MAP kinase cascades, by transient coexpression of reporter constructs containing binding sites for transcription factors targeted by these pathways and a SHP1 cDNA. Both pathways are inhibited by SHP1 as indicated by the lower induction of reporter gene activity. In conclusion, SHP1 regulates the transcriptional activity stimulated by the EPO-induced JAK/STAT and MAPK pathways and is involved in the signaling machinery responsible for erythroid differentiation and suppression of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595583     DOI: 10.1515/BC.1999.152

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

1.  Optimized Orbitrap HCD for quantitative analysis of phosphopeptides.

Authors:  Yi Zhang; Scott B Ficarro; Shaojuan Li; Jarrod A Marto
Journal:  J Am Soc Mass Spectrom       Date:  2009-03-28       Impact factor: 3.109

2.  Erythroblast transformation by the friend spleen focus-forming virus is associated with a block in erythropoietin-induced STAT1 phosphorylation and DNA binding and correlates with high expression of the hematopoietic phosphatase SHP-1.

Authors:  Kazuo Nishigaki; Charlotte Hanson; Takashi Ohashi; Angelo Spadaccini; Sandra Ruscetti
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks.

Authors:  Sriram Sundaravel; Wen-Liang Kuo; Jong Jin Jeong; Gaurav S Choudhary; Shanisha Gordon-Mitchell; Hui Liu; Tushar D Bhagat; Kathy L McGraw; Sandeep Gurbuxani; Alan F List; Amit Verma; Amittha Wickrema
Journal:  Clin Cancer Res       Date:  2019-07-15       Impact factor: 12.531

4.  Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias : combination analysis with cDNA expression array and tissue microarray.

Authors:  T Oka; T Yoshino; K Hayashi; N Ohara; T Nakanishi; Y Yamaai; A Hiraki; C A Sogawa; E Kondo; N Teramoto; K Takahashi; J Tsuchiyama; T Akagi
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

5.  SHP-1 inhibition by 4-hydroxynonenal activates Jun N-terminal kinase and glutamate cysteine ligase.

Authors:  Alessandra Rinna; Henry Jay Forman
Journal:  Am J Respir Cell Mol Biol       Date:  2008-02-14       Impact factor: 6.914

6.  Oral administration of penta-O-galloyl-β-D-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition.

Authors:  Hyo-Jeong Lee; Nam-Jun Seo; Soo-Jin Jeong; Yongjin Park; Deok-Beom Jung; Wonil Koh; Hyo-Jung Lee; Eun-Ok Lee; Kwang Seok Ahn; Kyoo Seok Ahn; Junxuan Lü; Sung-Hoon Kim
Journal:  Carcinogenesis       Date:  2011-02-02       Impact factor: 4.741

7.  Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.

Authors:  Christos Demosthenous; Jing Jing Han; Guangzhen Hu; Mary Stenson; Mamta Gupta
Journal:  Oncotarget       Date:  2015-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.